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Objective. To assess the eﬀect of combined diazoxide-metformin therapy in obese adolescents treated for craniopharyngioma.
Design. A prospective open-label 6-month pilot treatment trial in 9 obese subjects with craniopharyngioma. Diazoxide (2mg/kg
divided b.i.d., maximum 200mg/day) and metformin (1000mg b.i.d.). Whole body insulin sensitivity index (WBISI) and area-
under-the-curve insulin (AUCins)w e r ec a l c u l a t e d .Results. Seven subjects completed: 4M/3F, mean ± SD age 15.4 ± 2.9 years,
weight 99.7 ± 26.3kg, BMI 35.5 ± 5.6kg/m 2, and BMI SDS 2.3 ± 0.3. Two were withdrawn due to vomiting and peripheral
edema. Of participants completing the study, the mean ± SD weight gain, BMI, and BMI SDS during the 6 months were reduced
compared to the 6 months prestudy (+1.2 ± 5.9v e r s u s+ 9 .5 ± 2.7kg,P = .004; −0.3 ± 2.3v e r s u s+ 2 .2 ± 1.5kg/m 2, P = .04;
−0.04 ± 0.15 versus +0.11 ± 0.08, P = .021, resp.). AUCins correlated with weight loss (r = 0.82, P = .02) and BMI decrease
(r = 0.96, P = .009). Conclusion. Combined diazoxide-metformin therapy was associated with reduced weight gain in patients
with hypothalamic obesity. AUCins at study commencement predicted eﬀectiveness of the treatment.
1.Introduction
Craniopharyngiomas constitute 9% of childhood intracra-
nial tumors. They are histologically benign, arising from
embryonalremnants in the sellarregion [1,2].Inaddition to
endocrine deﬁciencies, obesity is common following surgical
resection of the tumor, with a signiﬁcant increase in long-
term cardio- and cerebrovascular mortality observed [3–5].
Data from our group, in 17 obese youth with craniopharyn-
gioma, show signiﬁcantly more features of the metabolic
syndrome (66% versus 15%), higher acute insulin secretion
in response to an oral glucose tolerance test (OGTT), and
a higher prevalence of glucose intolerance (40% versus 0%)
compared to age- and BMI-matched controls [6].
The mechanisms contributing to hypothalamic obesity
following surgery for craniopharyngioma, likely include one
or both of the following: (i) damage to hypothalamic nuclei
and neuronal circuits involved in appetite and body weight
regulation and (ii) a primary defect of insulin hypersecretion
due to hypothalamic damage-induced vagal eﬀerent stimu-
lation with increased weight gain and compensatory insulin
resistance [7, 8].
Giventheseriouschallengesposedbytheongoingweight
gain and the lack of eﬀective interventions, we developed a
novel therapeuticapproachwithcombinationtherapy aimed
both at decreasing insulin secretion using diazoxide and
simultaneously enhancing insulin action through the use of
metformin.2 International Journal of Pediatric Endocrinology
Neither metformin nor diazoxide the combination has
been tested previously in children with hypothalamic obesity
due to intracranial damage. The oral route of medication
administration, safety proﬁle, decreased cost, and their
mechanisms of action support their use in combination
in this situation. We hypothesized that the combined met-
formin and diazoxide therapy would lower insulin secretion
while minimizing the risk of hyperglycemia, leading to
weight loss and improvement in metabolic status.
2.MaterialsandMethods
An open-label, 6-month duration, pilot treatment trial of
combined diazoxide-metformin treatment was employed in
children with obesity following craniopharyngioma surgery.
Forty-six children under the age of 19 years treated sur-
gically for craniopharyngioma tumour are currently being
followed at the Hospital for Sick Children, Toronto. Approx-
imately 50% are obese deﬁned by a BMI ≥ 95th centile for
age and gender assessed from the updated Centre for Disease
Control growth charts [9]. All of these children have hypopi-
tuitarism requiring hormone replacement therapy. They
are assessed regularly in our comprehensive care clinic for
children with tumour-related hypothalamic obesity. This is a
multidisciplinary care setting staﬀed by an endocrinologist,
dietitian,exerciseconsultant,andpsychologistwithexpertise
in treatment of obesity. Patients may attend monthly to
receive support in regard to lifestyle counseling.
Subjects who met the following inclusion criteria were
recruited into the study:
(i) history of a craniopharyngioma in the sellar/supras-
ellar region with hypothalamic involvement at least
one year following surgery;
(ii) stable hormone replacement therapy for more than
one year (with one or more of thyroxine, hydro-
cortisone, desmopressin, sex steroids, and growth
hormone);
(iii) obesity, deﬁned as BMI > SDS for age and gender,
or those with BMI < 85th percentile before tumor
diagnosis but weight gain >2SD above mean for age
for 1 year following tumor treatment. These criteria
were chosen based on studies in this population
showing favourable changes using a long-acting
octreotide analogue [10];
(iv) age 9–19 years;
(v) minimum of 6 months of standard diet and exercise
intervention in our existing comprehensive care
clinic (run-in period). During this time, individuals
met with each of the interdisciplinary team members
atthemonthlyclinictolearnaboutincreasedphysical
activity, healthy dietary intake and receive psycho-
logic support to promote change in behavior. This
time frame was chosen to allow a period of prospec-
tive measurements to establish individual baseline
slope of change in BMI SDS prior to initiation of
active treatment with diazoxide and metformin.
Exclusion criteria included the following.
(i) Contraindications for metformin or diazoxide use
(history or evidence of cardiac, renal, or progressive
hepatic disease, diabetes, or hypoxic conditions).
(ii) Pharmacologic doses of glucocorticoids or use of
other medications known to aﬀect glucose metabo-
lism (e.g., beta-blockers, oral hypoglycemics) within
6 months of study onset.
(iii) Growth hormone (GH) initiation in the preceding 6
months or planned initiation in the next 6 months
(to rule out potential confounding eﬀect of GH on
weight/body composition and glucose metabolism).
(iv) Use of other weight loss medications.
(v) Inability of the family and/or patient to comply with
study protocol.
(vi) Non-English speaking.
3. Treatment Protocol
Following a 6-month period of diet and exercise coun-
seling, subjects received diazoxide (2mg/kg divided b.i.d.,
maximum 200mg/day divided twice daily) and metformin
(2000mg per day divided twice daily) given with meals for
6 months. This dose of diazoxide was chosen because it ﬁts
within the pediatric dosing guidelines to treat children with
hyperinsulinism (3–8mg/kg/day) and is similar to that used
in previous studies in obese adults (100mg b.i.d-t.i.d.) [11].
Diazoxide was initiated at half the dose (100mg per
day) for 2 weeks to allow the insulin sensitizing action of
metformin to take eﬀect. Metformin was initiated at 500mg
twice daily and increased to 1000mg twice daily over a
one-week period to minimize gastrointestinal side eﬀects.
This dose is typically used in adolescents and adults with
polycystic ovarian disease or type 2 diabetes [12].
4.Baseline andPosttreatment Assessment
4.1. History and Physical Exam. Family and medical history
wasobtainedfromthehospitalchartduringclinicreviewand
from the patient. Information obtained included duration
since surgery for the tumor, endocrine sequelae, family
history of metabolic syndrome (hypertension, dyslipidemia,
cardiovascular disease, type 2 diabetes), and current medica-
tions. Physical examination included assessment of systolic
and diastolic blood pressure recorded as the mean of 3
readings taken 1 minute apart in the right arm in the seated
position using a Dinamap device and appropriately sized
cuﬀ. Puberty was assessed using the staging method of Tan-
ner [13, 14]. A standard, calibrated scale and wall-mounted
stadiometer were used to measure weight and height, and
BMI was calculated as wt(kg)/ht(m)2. BMI standard devi-
ation scores (SDS) were calculated based on data from the
Center Disease Control (http://www.cdc.gov/nccdphp/dnpa/
growthcharts/resources/sas.htm).International Journal of Pediatric Endocrinology 3
4.2. Glucose and Insulin Dynamics. Following an overnight
fast,subjectsarrivedattheClinicalInvestigationUnitat8:00
AM for an OGTT (1.75mg/kg, max 75g), and venous blood
samples were obtained at 0, 30, 60, 90, and 120 minutes to
screen for impaired glucose tolerance and type 2 diabetes
[15]. Using values derived from the OGTT, whole body
insulin sensitivity index (WBISI) was calculated using the
Matsuda index calculated as 10,000/
√
((fasting glucose ×
fasting insulin) × (mean glucose × mean insulin)), where
glucose is measured in mmol/L and insulin in pmol/L. This
has been validated against gold-standard measures of insulin
sensitivity in adults and in children [16, 17]. The area under
the curve of insulin (AUCins) during OGTT was calculated
as an index of insulin secretion using the trapezoid method
[18].
Insulin was measured by chemiluminescence using the
Siemens Immulite 2500 (range of assay 15–2165pmol/L,
intra- and interassay coeﬃcient of variation (CV) <7.6%).
Leptin was measured using enzyme-linked immunosor-
bent assay supplied by Diagnostic Systems Laborato-
ries Inc. (range 0.1–50.0ng/mL; interassay CV 1.5–6.2%).
Adiponectin was measured by ELISA (Linco Research Inc.,
range: 1–100ng/mL; interassay CV 2.4–8.4%). Adiponectin
and leptin are synthesized and secreted from adipose tissue
and are correlated negatively and positively, respectively, to
insulin resistance and obesity in children and adolescents
[19–22]. Fasting triglycerides (TG), total cholesterol, LDL,
high-densitylipoprotein(HDL)cholesterol,andapolipopro-
teins were measured by standard enzymatic methods. Low-
density lipoprotein (LDL) cholesterol was calculated using
the following formula: LDL cholesterol = total cholesterol −
TG/2.2 + HDL cholesterol.
5.Monitoring
Subjects were assessed monthly for dietary and exercise
consultation receiving ongoing support similar to the 6-
month run-in period and monitoring of side eﬀects of
medication. Subjects were also contacted by phone weekly
for the ﬁrst month to review potential side eﬀects and were
taught to perform urine dipstick to assess for glucosuria.
Development of diabetes or signiﬁcant medication side
eﬀects were considered reasons for withdrawal. Compliance
was assessed at monthly visits by tablet count.
This study was approved by the Research Ethics Board
at the Hospital for Sick Children, Health Canada Clin-
ical Trials Application (http://clinicaltrials.gov/, identiﬁer:
NCT00892073). Informed consent was obtained from both
parents and subjects prior to study commencement. A Data
Safety Monitoring Committee (DSMC) received monthly
reports of recruitment, laboratory results, and any adverse
events and met every 3 months during the study duration.
They also received immediate notiﬁcation of any serious
adverse events.
6. StatisticalAnalysisandPower Calculation
Statistical analysis was performed using SAS software (SAS
version 8.2, Cary, NC, 1999). Continuous variables were
expressed as mean and standard deviation. Comparisons
of weight parameter changes, biochemical tests, and cal-
culated indices of insulin secretion and sensitivity in the
6 months prior to study entry and during the 6 months
on study medication were compared using the paired t-test
with Bonferroni correction for multiple t-tests. Pearson’s
correlation analysis was performed between measures of
changes in weight parameters and biochemical parameters
at study onset (AUCins, WBISI, leptin, adiponectin). Log
transformations were performed on nonnormative variables
for analyses and back-transformed for data presentation.
For this pilot study, it was estimated that recruitment
of 8 subjects should be adequate to achieve 80% power to
detectadiﬀerenceofchangeinBMIof2.1kg/m2 betweenthe
6-month run-in period and the 6-month treatment period
based on a pilot study of octreotide in a similar population
[8].
7. Results
Nine (4 female) subjects were eligible and all consented to
participate. All had evidence of hypothalamic damage on
MRI following surgical treatment for craniopharyngioma.
Twosubjectsdidnotcompletethestudysecondarytoadverse
medicationeﬀects.Onefemalesubjectwaswithdrawnafter2
monthsoftreatmentduetothedevelopmentofpedaledema.
A second female participant was withdrawn after 4 months
of treatment due to mildly elevated hepatic enzyme levels
(ALT 120; AST 134 U/L) and vomiting. These adverse events
resolved after medication cessation. Blood pressure and
glucose tolerance remained normal in all of the participating
subjects.
Considering the seven subjects completing the study, the
mean ± SD age was 15.4 ± 2.9 years, time since diagnosis
5.9 ± 2.0 years, and Tanner stage 2.9 ± 1.6. The mean ±
SD weight was 99.7 ± 26.3kg, BMI35.5 ± 5.6kg/m 2,a n d
BMISDS2.3 ± 0.3.Allparticipantshadpanhypopituitarism,
requiring hormone replacement, and were receiving levo-
thyroxine, hydrocortisone, and desmopressin replacement.
Seven were receiving growth hormone (mean 15.4 ± 2.9
years), and 8 were receiving sex steroid replacement. All had
normal glucose levels both fasting and 2 hours following
an OGTT. Patient characteristics at baseline are provided
in Table 1, and biochemical tests before and after study are
shown in Table 2.
Of participants completing the study, the mean ± SD
weight gain during the 6 months of the study was signiﬁ-
cantly reduced compared to that in the 6 months prestudy
(+1.2 ± 5.9v e r s u s+ 9 .5 ± 2.7kg,P = .0035) (Figure 1(a)).
The mean BMI (−0.3 ± 2.3v e r s u s+ 2 .2 ± 1.5kg/m 2, P =
.02) was also signiﬁcantly reduced during the study period
(Figure 1(b)). The change in BMI SDS was also signiﬁcantly
reduced in the 6 months during the study period (−0.04 ±
0.15 versus +0.11 ± 0.08, P = .021) (Figure 1(c)).
AUCins atthe commencementof the study wascorrelated
with weight loss (r = 0.82, P = .02) and BMI decrease
(r = 0.96,P = .009)duringthestudy(Figure 2).Thepositive
correlation between WBISI and BMI decrease approached
statistical signiﬁcance (r = 0.75, P = .05) while that with4 International Journal of Pediatric Endocrinology
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Figure 1: Changes in individual (a) weight, (b) BMI, and (c) BMI
SDS during the 6 months before (light bars) and after 6 months
(dark bars) of metformin-diazoxide treatment.
weight did not (r = 0.6, P = .12). There was no signiﬁcant
correlation between any of the weight parameters and leptin
or adiponectin at the start of the study (data not shown).
Figure 3 provides an example of the pre- and posttreatment
insulin curves in a “responder” and a “nonresponder.”
8. Discussion
In this study, a novel therapeutic approach based on
combined treatment both to decrease insulin secretion using
diazoxide and at the same time enhancing insulin action
through the use of metformin was utilized to treat children
with hypothalamic obesity secondary to craniopharyngioma
surgery. Overall, our subjects exhibited a decrease in weight
gain and BMI during the 6-month treatment period,
althoughtherewassomevariabilityinresponsetotreatment.
Three of seven subjects lost weight during the treatment
period; however, all exhibited less weight gain than in the
preceding 6 months. Most interestingly, subjects with the
highest insulin secretion at the start of the study experienced
the greatest weight loss response to therapy.
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Figure 2: BMI Change during 6 months treatment with diazoxide
and metformin relative to AUCins at the beginning of Treatment
(r = 0.96, P = .009).
Two synergistic mechanisms likely contribute to the
hypothalamic obesity following surgery for craniopharyn-
gioma, although their relative contributions are not known:
(i) damage to hypothalamic nuclei and neuronal circuits
involved in appetite and body weight regulation and (ii) a
primary defect of insulin hypersecretion due to hypotha-
lamic damage-induced vagal eﬀerent stimulation with
increased weight gain and compensatory insulin resistance
[7, 8]. Damage to critical areas involved in hunger, satiety,
and energy homeostasis impairs signaling and feedback
mechanisms. Experimental rat models, following damage
to the ventromedial (VMH) hypothalamus, demonstrate
hyperphagia,obesity,hyperinsulinism,andinsulinresistance
[23]. Furthermore, pancreatic vagotomy in these animals
results in weight loss, implicating the role of insulin hyper-
secretion in their weight gain [7]. There is a case report
of a woman with hypothalamic obesity who responded to
truncalvagotomywithsigniﬁcantweightloss[24].Enhanced
vagal eﬀerent stimulation leading to exaggerated insulin
release may occur via several mechanisms. These include
(i) a “cephalic” or premeal vagal stimulation of muscarinic
receptors linked to sodium channel in the pancreatic β-
cell membrane resulting in slight depolarization and “prim-
ing” of the β cell for glucose-mediated depolarization, (ii)
increased production of β-cell phospholipases important
for downstream mediators of intracellular and vesicular
release of calcium and insulin, and (iii) stimulation of
the insulin secretagogue glucagon-like peptide-1 (GLP-1)
from intestinal L cells [25]. There is also some suggestions
that decreased sympathetic tone may also contribute to
autonomic dysregulation and hypothalamic obesity [26].
A recent pilot study of caﬀeine and ephedrine given to 3
patientswithhypothalamicobesityresultedinameanweight
loss of 14% with 2 of the 3 patients sustaining weight loss for
at least 2 years [27].
In this study, diazoxide was chosen as the therapeutic
agent as it eﬀectively decreases insulin release by binding
to the KATP channel and preventing closure [11]. Oral
diazoxide is used primarily in the treatment of neonatal and
childhood hyperinsulinemic hypoglycemia at doses of 3–
8mg/kg/day[11]. Diazoxide has been evaluated in one study
in 24 obese hyperinsulinemic adults to promote weight lossInternational Journal of Pediatric Endocrinology 5
Table 1: Patient characteristics at baseline.
Subject Age
(years) Sex Years
since Dx
Weight
(kg)
BMI
(kg/m2)
BMI SDS
1 15.8 F 4.4 95.5 34.7 2.03
2 18.3 F 4.7 135.3 45.4 2.41
3 16.2 F 6.3 92.4 35.4 2.00
4∗ 11.4 F 5.7 66.0 32.8 2.32
5 16.1 M 8.0 121.6 37.7 2.54
6∗ 15.9 F 8.7 156.5 65.1 2.96
7 14.7 M 7.3 75.7 28.3 1.8
8 17.1 M 8.1 112.0 34.0 2.14
9 9.2 F 2.8 56.8 29.6 2.48
Dx: diagnosis of craniopharyngioma; BMI: body mass index; SDS: standard
deviation score. ∗Denotes subjects who were withdrawn from the study
due to vomiting with mild elevation of hepatic enzymes (subject 4) and
peripheral edema (subject 6).
Table 2: Biochemical measures at baseline and after 6 months of
treatment (mean ± SD).
Test Initial Final
Fasting TG (mmol/L) 1.97 ± 1.05 1.96 ± 0.63
HDL (mmol/L) 1.00 ± 0.30 0.93 ± 0.41
LDL (mmol/L) 2.18 ± 0.94 2.43 ± 0.91
Total cholesterol (mmol/L) 4.07 ± 0.81 4.26 ± 0.90
WBISI 2.2 ± 1.1 5.7 ± 8.1
AUCins (pmol/L) 2078.8 ± 668.8 1438.3 ± 988.5
Adiponectin (mg/mL) 10.01 ± 4.39 8.17 ± 3.46
Leptin (ng/mL) 27.64 ± 22.14 23.55 ± 25.34
HbA1c (%) 5.0 ± 0.3 4.8 ± 0.5
AST (U/L) 31.0 ± 6.95 30.4 ± 16.80
ALT (U/L) 28.3 ± 7.45 40.4 ±48.79
Fasting glucose (mmol/L) 4.4 ± 3.60 4.7 ± 0.69
Fasting insulin (pmol/L) 174.3 ± 87.79 130.2 ± 99.56
2 hour glucose (mmol/L) 5.4 ± 0.96 6.2 ± 1.36
2 hour insulin (pmol/L) 995.3 ± 531.19 735.0 ± 683.97
Pvalue:notsigniﬁcantforallvariablesshownabove.TG:triglycerides;HDL:
high-density lipoprotein cholesterol; LDL: low-density lipoprotein choles-
terol; WBISI: whole body insulin sensitivity index; AUCins:a r e a - u n d e r - t h e -
curve insulin; HbA1c: hemoglobin A1c; AST: aspartate aminotransferase;
ALT: alanine aminotransferase.
at doses of 2 mg/kg per day (up to 200mg daily) for 8 weeks.
Treatment resulted in a greater weight loss (9.5 ± 0.69%
versus 4.6 ± 0.61%, P<. 001), greater decrease in body fat
(−9.3 ± 1.0kgversus −3.6 ± 0.9kg,P<. 01), and greater
attenuation of acute insulin response to glucose compared
to a low calorie diet alone. It was well tolerated, without
glucose intolerance [28]. Octreotide, another agent used in
the treatment of hyperinsulinemic hypoglycemia, has been
studied as a weight loss agent in the context of hypothalamic
obesity. In a 6-month pilot octreotide treatment trial in 8
obese children with hypothalamic obesity, children exhibited
aw e i g h tl o s so f4 .8 ± 1.8kg (P = .04) and a decrease in
BMI (2.0 ± 0.7kg/m 2, P = .012). The degree of weight
loss correlated to the change in insulin response [8]. A
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Figure 3: Insulin secretion before and after treatment and changes
in BMI in a responder (a) and a nonresponder (b).
randomized controlled trial of long-acting octreotide by the
same group was performed in 172 obese adults with insulin
hypersecretion, deﬁned by OGTT. Weight loss during this
study was modest, approximately 2%, with a corresponding
decrease in BMI of approximately 0.75kg/m2. As in the
hypothalamicobesitystudywithoctreotideinchildren,those
with higher insulin secretion at study start gained the most
beneﬁt in terms of weight loss [10].
One of the signiﬁcant concerns of the use of diazoxide
and other agents to decrease insulin secretion is the potential
to lead to signiﬁcant side eﬀects including gastrointestinal
disturbances, biliary gallstones, edema, and hyperglycemia.
In our study, 2 subjects were withdrawn, one for signiﬁ-
cant gastrointestinal symptoms and the second due to the6 International Journal of Pediatric Endocrinology
developmentofperipheraledema.Wedidnotexperienceany
subjects developing hyperglycemia, and this may have been
due to the addition of metformin.
Metformin is an oral antihyperglycemic agent which
acts predominantly to decrease hepatic gluconeogenesis
and has a modest eﬀect on peripheral glucose uptake
into insulin-sensitive tissues. In adults with and without
diabetes, metformin has been associated with weight loss or
a decreased rate of weight gain and body fat accumulation
[29]. This can be attributed to both a net decrease in caloric
intake due to appetite suppression and beneﬁcial eﬀects
from improvement of insulin and glucose dynamics. Four
randomized placebo-controlled trials with treatment of 1000
to 1700mg divided twice daily, of 2–6 month duration
in obese (BMI > 30kg/m2) adolescents, showed modest
reduction in BMI, serum leptin, glucose, and insulin levels
and an increase in insulin sensitivity [29–32]. The largest of
these studies conducted over a 6-month period in 120 obese
adolescents demonstrated a statistically signiﬁcant decline
in body mass index (from 28.5 ± 3.4t o2 6 .7 ± 4.0kg/m 2,
P<. 001) [30].
Our study is limited by the small number of participants
and lack of randomization. It is possible that the most moti-
vated individuals chose to participate in the study and that
their improvement was related to ongoing lifestyle changes
ratherthanmedication perse. However,the factsthatinsulin
decreased in those who lost most weight and increased AUC
insulin prior to treatment predicted improved response to
medication suggest that mechanisms related to therapy (in
particular, diazoxide) led to favourable changes in weight.
It is not possible from this study to dissect out fully,
whether diazoxide or metformin alone would have led to
similar results. Further studies in this population will be
required.
In children with hypothalamic obesity with demon-
strated inexorable weight gain and who are at very high risk
for cardiometabolic complications, we found that combina-
tion treatment with diazoxide and metformin resulted in less
weight gain and favourable changes in BMI. Although the
medication was generally well tolerated, two subjects were
withdrawn, one due to side eﬀects of diazoxide (edema) and
the second to adverse gastrointestinal symptoms secondary
to metformin. This highlights the need for careful monitor-
ing when using these medications. The outcome of this pilot
study is encouraging and does provide necessary data for
a larger randomized trial in individuals with hypothalamic
obesity including children with craniopharyngioma and
others who exhibit hypersecretion of insulin. If also positive,
this would lead to extrapolation of this approach to other
obese, hyperinsulinemic groups.
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